700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
|Stellar Bio molecular Research (SBR) and FCTI, Germany|
|ScientificTracks Abstracts: J Nephrol Ther|
|Chronic Kidney Disease (CKD) is characterized by progressive deterioration of renal function due to loss of functioning nephrons. In spite of available treatments, CKD is still considered as irreversible, with gradually worsening condition that ultimately results in End-Stage Renal Failure (ESRF). Such situation urges to seek for new advanced therapeutic modalities that are able to restore renal function or at least substantially slow down the progression of CKD. Recent research and studies has shown that the most promising opportunity to restore nephron functionality is stem cell therapy. Due to morphological complexity of the kidney’s ultrastructure the available options of autologous stem cell therapy has proven its failure to restore the anatomy and functionality of nephron. On the other hand embryonic and induced pluripotent stem cells have multiple unsolved safety issues. Latest scientific developments demonstrate that fetal precursor stem cells transplantation is the safest and most reliable method of renal cellular pool replacement in patients with CKD. In our study, we present data on efficacy of combination of precursor stem cells (FCTI) and targeted organ-specific peptides (SBI, MF+, Germany) in patients with CKD. Results of stem cell implantation were evaluated 6 months and 1 year after the procedure. Certain improvements of parameters of renal function test and downstaging of CKD, depending on the stage of the disease, were noted. There were no adverse reactions observed in treated patients. Precursor stem cells and organ-specific peptides (SBI, MF+, Germany) in management of CKD is a promising therapeutic modality and requires further detailed analysis and continued clinical trials.|
Dmitry Klokol, upon completion of Medical Degree and further specialization in General Surgery has proceeded with PhD in Surgery in Institute of Emergency and Reconstructive Surgery and Post-doctoral study in the Field of Regenerative Medicine and Cell Therapy. He has vast clinical, academical and research experience in surgery, anti-aging, regenerative, complementary medicine and cell therapy. He has published more than 50 articles, 2 books and is a Member of the Editorial Board in one of American journals. At present, he is Head of Medical Advisory Board in International Biomolecular Research Company and Medical Director of European Wellness Centers.
|PDF | HTML|